Barker L J, Jones S E, Savin M A, Mennel R G
Texas Oncology, PA, Denison 75020.
Cancer. 1993 Aug 1;72(3):771-3. doi: 10.1002/1097-0142(19930801)72:3<771::aid-cncr2820720322>3.0.co;2-9.
BACKGROUND. New salvage chemotherapy is needed for metastatic breast cancer. Cisplatin and VP-16 have activity but considerable toxicity.
This study determines the response rate, response duration, and toxicity of a combination chemotherapy regimen of the better-tolerated carboplatin plus VP-16 in a group of patients with metastatic breast cancer and only one prior exposure to cytotoxic chemotherapy.
Twenty-three patients received an average of 2.8 courses of treatment before a lack of response or progression of disease was noticed. Four patients had evidence of rapidly progressive disease or early death and received only one course. No complete responses occurred, but three patients (13%) experienced partial responses. Mean response duration was 5 months. Metastatic disease which responded included lung, lymph node, and chest wall sites. Toxicity was mainly myelosuppression with 57% of patients having grade 3-4 neutropenia or thrombocytopenia. Two patients (8%) had significant infection with neutropenia requiring hospitalization but no toxic deaths occurred.
Carboplatin and VP-16 at this dose and schedule was a reasonably well-tolerated regimen with only modest activity in metastatic breast cancer as second-line cytotoxic chemotherapy.
背景。转移性乳腺癌需要新的挽救性化疗方案。顺铂和依托泊苷有活性，但毒性较大。
本研究确定了在一组转移性乳腺癌患者中，采用耐受性较好的卡铂联合依托泊苷的联合化疗方案的缓解率、缓解持续时间和毒性，这些患者之前仅接受过一次细胞毒性化疗。
23例患者在疾病无反应或进展之前平均接受了2.8个疗程的治疗。4例患者有疾病快速进展或早期死亡的证据，仅接受了1个疗程的治疗。未出现完全缓解，但3例患者（13%）出现部分缓解。平均缓解持续时间为5个月。有反应的转移性疾病部位包括肺、淋巴结和胸壁。毒性主要是骨髓抑制，57%的患者出现3-4级中性粒细胞减少或血小板减少。2例患者（8%）因中性粒细胞减少发生严重感染需要住院治疗，但未发生毒性死亡。
卡铂和依托泊苷按此剂量和疗程是一种耐受性较好的方案，作为转移性乳腺癌的二线细胞毒性化疗，活性仅为中等。
